{"id":"NCT01391546","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)","officialTitle":"An Open-label, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ZOSTAVAX When Administered by Intramuscular Route or Subcutaneous Route to Subjects of 50 Years of Age and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06-20","primaryCompletion":"2012-10-15","completion":"2012-10-15","firstPosted":"2011-07-12","resultsPosted":"2017-11-20","lastUpdate":"2019-01-09"},"enrollment":354,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"ZOSTAVAX","otherNames":["V211"]}],"arms":[{"label":"ZOSTAVAX intramuscular (IM) route","type":"EXPERIMENTAL"},{"label":"ZOSTAVAX subcutaneous (SC) route","type":"ACTIVE_COMPARATOR"}],"summary":"PRIMARY OBJECTIVES\n\nTwo co-primary objectives are:\n\n* To demonstrate that the immunogenicity of ZOSTAVAX administered by intramuscular route (IM) is non-inferior to ZOSTAVAX administered by subcutaneous route (SC)\n* To demonstrate that ZOSTAVAX administered by IM route induces an acceptable fold-rise of varicella zoster virus (VZV) antibody titre from pre to 4-week post-vaccination\n\nSECONDARY OBJECTIVES\n\nImmunogenicity objectives\n\n* To evaluate the immunogenicity as measured by VZV antibody titre at 4 weeks following ZOSTAVAX administered by IM or SC route\n* To evaluate the immune response as measured by a second assay, the VZV Interferon gamma Enzyme-linked immunospot (ELISPOT) at 4 weeks following ZOSTAVAX administered by IM or SC route\n\nSafety objective\n\n\\- To describe the safety profile of ZOSTAVAX administered by IM or SC route","primaryOutcome":{"measure":"Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination","timeFrame":"4 week post-vaccination","effectByArm":[{"arm":"ZOSTAVAX Intramuscular (IM) Route","deltaMin":395.3,"sd":null},{"arm":"ZOSTAVAX Subcutaneous (SC) Route","deltaMin":391.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25555381"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":176},"commonTop":["Injection site erythema","Injection site pain","Injection site swelling","Injection site pruritus"]}}